NASDAQ$OMGAQ
Omega Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Announced promising clinical data for OTX-2002 and advanced OMEGA platform capabilities.
Omega Therapeutics reported third quarter results with a net loss of $22.2 million. The company highlighted promising preliminary clinical data for OTX-2002 and the advancement of its OMEGA platform.
- Promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial was announced.
- Clinical proof-of-platform established with potential applicability across a broad range of diseases.
- Advanced OMEGA platform capabilities and presented new preclinical data on multiple epigenomic controller programs at medical meetings.
- Board of Directors strengthened with appointment of Chris Schade as Chairman and addition of Michelle C. Werner.
Headline financials
Revenue & EPS history
Omega Therapeutics · Revenue · Quarterly
$831K
Forward guidance
Omega expects to report updated clinical data from monotherapy dose escalation in the first half of 2024 and is planning to initiate expansion cohorts in monotherapy and in combination settings with standard of care agents mid-2024.
Tailwinds
- OTX-2002 continues to advance in monotherapy dose escalation.
- The Company is actively evaluating patients with HCC in Cohort 3.
- Omega expects to report updated clinical data from monotherapy dose escalation in the first half of 2024.
- The Company is planning to initiate expansion cohorts in monotherapy.
- The Company is planning to initiate expansion cohorts in combination settings with standard of care agents mid-2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 9 quarterly earnings reports · overlaid with Q3 2023
-5.1%
Avg return
Earnings day
-8.9%
Avg return
5 days after
-12.9%
Avg return
30 days after
47%
7 / 15 earnings
Positive
+14.2%
Q1 2023
Best reaction
-47.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -47.5% | -25.0% | -44.8% | |
| Q3 2024 | -22.6% | -30.7% | -9.2% | |
| Q2 2024 | -0.6% | +0.0% | -11.3% | |
| Q1 2024 | -16.7% | -16.1% | -17.3% | |
| Q4 2023 | -9.9% | -15.3% | -36.6% | |
| Q3 2023 | -3.4% | +5.1% | +28.7% | |
| Q2 2023 | +2.4% | -14.2% | -23.8% | |
| Q1 2023 | +14.2% | +9.1% | +4.4% | |
| Q4 2022 | +5.6% | +7.0% | -6.7% | |
| Q3 2022 | -3.8% | — | — | |
| Q2 2022 | +9.3% | — | — | |
| Q1 2022 | +0.3% | — | — | |
| Q4 2021 | -6.4% | — | — | |
| Q3 2021 | +1.5% | — | — | |
| Q2 2021 | +0.9% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro